Insider Selling: MacroGenics Inc (MGNX) SVP Sells 3,000 Shares of Stock

Share on StockTwits

MacroGenics Inc (NASDAQ:MGNX) SVP Eric Blasius Risser sold 3,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $18.38, for a total transaction of $55,140.00. Following the transaction, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $621,354.28. The sale was disclosed in a document filed with the SEC, which is available through this link.

Eric Blasius Risser also recently made the following trade(s):

  • On Wednesday, May 22nd, Eric Blasius Risser sold 4,000 shares of MacroGenics stock. The stock was sold at an average price of $18.54, for a total transaction of $74,160.00.

MGNX stock traded up $0.23 on Thursday, reaching $18.66. 33,830 shares of the company traded hands, compared to its average volume of 931,225. MacroGenics Inc has a one year low of $9.87 and a one year high of $32.32. The company has a quick ratio of 6.47, a current ratio of 6.47 and a debt-to-equity ratio of 0.08. The firm has a market cap of $914.62 million, a PE ratio of -4.42 and a beta of 2.90.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.04). The business had revenue of $9.66 million during the quarter, compared to the consensus estimate of $11.46 million. MacroGenics had a negative return on equity of 57.65% and a negative net margin of 256.47%. On average, research analysts expect that MacroGenics Inc will post -3.7 earnings per share for the current fiscal year.

MGNX has been the topic of several recent research reports. HC Wainwright set a $39.00 price objective on shares of MacroGenics and gave the stock a “buy” rating in a research note on Wednesday, February 20th. Nomura upped their target price on MacroGenics from $41.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, February 7th. SunTrust Banks increased their price objective on MacroGenics to $40.00 and gave the company a “buy” rating in a research report on Thursday, February 7th. Citigroup upgraded MacroGenics from a “sell” rating to a “buy” rating and increased their price objective for the company from $10.00 to $39.00 in a research report on Thursday, February 7th. Finally, Cowen restated a “buy” rating on shares of MacroGenics in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $32.07.

Several institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in shares of MacroGenics by 3.7% in the first quarter. The Manufacturers Life Insurance Company now owns 25,971 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 929 shares in the last quarter. Legal & General Group Plc lifted its position in shares of MacroGenics by 20.4% in the fourth quarter. Legal & General Group Plc now owns 7,432 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 1,261 shares in the last quarter. Northern Trust Corp lifted its position in shares of MacroGenics by 0.3% in the fourth quarter. Northern Trust Corp now owns 524,500 shares of the biopharmaceutical company’s stock worth $6,661,000 after buying an additional 1,644 shares in the last quarter. Stifel Financial Corp lifted its position in shares of MacroGenics by 14.8% in the fourth quarter. Stifel Financial Corp now owns 18,034 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 2,327 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in shares of MacroGenics in the first quarter worth about $59,000. 87.02% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Zolmax and is the sole property of of Zolmax. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://zolmax.com/investing/insider-selling-macrogenics-inc-mgnx-svp-sells-3000-shares-of-stock/3093227.html.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Article: Blockchain

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Expect Bank of Hawaii Co.  to Announce $1.38 Earnings Per Share
Analysts Expect Bank of Hawaii Co. to Announce $1.38 Earnings Per Share
Soarcoin 1-Day Trading Volume Tops $220.00
Soarcoin 1-Day Trading Volume Tops $220.00
Mason Graphite  Shares Up 5.6%
Mason Graphite Shares Up 5.6%
Continental Gold  Shares Up 0.7%
Continental Gold Shares Up 0.7%
Arcus Biosciences Inc  Short Interest Update
Arcus Biosciences Inc Short Interest Update
Hancock Whitney Corp  Given Average Rating of “Buy” by Analysts
Hancock Whitney Corp Given Average Rating of “Buy” by Analysts


 
© 2006-2019 Zolmax.